stockrow
Friday 6 November 2026
Export RCEL’s income statement to Excel — free account
Avita Medical Inc.
RCEL Healthcare Medical Devices
Avita Medical Inc.’s revenue for fiscal 2025 (year ended December 2025) was $71.6 million, up 11.5% from fiscal 2024.
- Revenue
- +53.1%
- EPS
- +56.9%
- Free cash flow
- +86.7%
- Total debt
- +7.13%
Quarter to September 2026, against a year earlier
16.61
0.93
+5.93%
Follow RCEL
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 5 Nov | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
1.34 | 1.56 | 1.68 | 4.28 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(17.68) | (11.22) | (36.33) | (509.94) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
2.27 | 2.58 | 2.70 | 5.24 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(5.21) | (6.02) | (8.42) | (22.50) | |
EV/FCF |
(4.92) | (5.72) | (8.02) | (22.07) | |
Quick Ratio |
0.44 | 0.36 | 0.31 | 0.90 | |
Current Ratio |
0.57 | 0.47 | 0.41 | 1.20 | |
Net Debt/EBITDA |
(2.56) | (3.72) | (6.39) | (8.54) | |
Debt/Assets |
76.22% | 89.51% | 97.66% | 97.18% | |
Debt/Equity |
(2.58) | (1.99) | (1.68) | (1.47) | |
Asset Turnover |
1.05 | 1.19 | 1.43 | 1.53 | |
Operating CF/Net income |
0.47 | 0.95 | 0.46 | 0.11 | |
Capex/Depreciation |
0.06 | (0.03) | (0.18) | (0.19) | |
Interest Coverage |
(8.30) | (6.46) | (4.22) | (3.17) | |
Research and Development Expense of Revenue |
32.30% | 29.24% | 23.40% | 17.99% | |
Selling, General and Administrative Expense of Revenue |
108.01% | 98.19% | 90.06% | 76.10% | |
Intangible Assets out of Total Assets |
0.10 | 0.11 | 0.11 | 0.12 | |
Share Based Compensation of Revenue |
7.79% | 5.72% | 9.16% | 6.39% | |
Graham Net Nets |
(0.39) | (0.38) | (0.37) | (0.14) | |
Graham Number |
4.84 | 5.17 | 5.41 | 5.15 | |
Earnings Yield |
(50.55%) | (42.26%) | (34.78%) | (9.99%) | |
Free Cash Flow Yield |
(34.36%) | (28.84%) | (20.03%) | (5.55%) | |
Revenue per Share |
0.63 | 0.63 | 0.71 | 0.85 | |
Operating CF per Share |
(0.20) | (0.33) | (0.11) | (0.02) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.19) | (0.33) | (0.12) | (0.03) | |
Cash per Share |
0.65 | 0.47 | 0.36 | 0.34 | |
Shareholders Equity per Share |
(0.60) | (0.76) | (0.91) | (1.01) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(0.60) | (0.76) | (0.91) | (1.01) | |
Free Cash Flow |
(5.40) | (10.09) | (3.60) | (0.82) | |
Working Capital |
(27.19) | (35.02) | (40.32) | 4.64 | |
Capital Expenditures |
0.04 | (0.02) | (0.11) | (0.11) | |
Net Current Asset Value |
(37.55) | (43.06) | (47.22) | (50.15) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.01 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
10.44 | 10.97 | 10.61 | 9.68 | |
Average Payables |
7.63 | 7.95 | 6.85 | 6.47 | |
Average Inventory |
7.10 | 7.26 | 6.41 | 6.02 | |
Average Assets |
68.05 | 60.55 | 52.96 | 55.26 | |
Average Common Equity |
(6.08) | (13.87) | (20.36) | (18.85) |
Columns are period end dates · fundamentals updated 5 Nov 2026